BioMed Research International

Volume 2014 (2014), Article ID 491492, 14 pages

http://dx.doi.org/10.1155/2014/491492

Research Article

Synthesis, Characterization, and In Vitro Anticancer Evaluation of Novel 2,5-Disubstituted 1,3,4-Oxadiazole Analogue

Salahuddin,¹ Avijit Mazumder,¹ and Mohammad Shaharyar²

¹Department of Pharmaceutical Technology, Noida Institute of Engineering and Technology, Greater Noida, Uttar Pradesh 201306, India

²Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi 110062, India

Received 26 February 2014; Revised 7 June 2014; Accepted 19 June 2014; Published 10 August 2014

Academic Editor: Filippo Canducci

Copyright © 2014 Salahuddin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

In this series, we have synthesised a new 2,5-disubstituted 1,3,4-oxadiazole in search of potential therapeutics for cancer. The anticancer activities were evaluated on a panel of 60 cell lines by the National Cancer Institute according to its own screening protocol. Out of the 24 compounds, 11 were selected and evaluated via single high dose (10⁻⁵ M). In the next phase, two compounds have been selected for five-dose assay. The compounds 3-(5-benzyl-1,3,4-oxadiazol-2-yl)quinolin-2(1H)-one 18 (NSC-776965) and 3-[5-(2-phenoxymethyl-benzoimidazol-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-2-p-tolyloxy-quinoline 27 (NSC-776971) showed mean growth percentage of 66.23 and 46.61, respectively, in one-dose assay and their GI₅₀ values ranging between 1.41–15.8 μM and 0.40–14.9 μM, respectively, in 5-dose assay.

1. Introduction

Cancer is primarily an environmental disease with 90–95% cases being related to environmental factors and 5–10% to genetics [1]. Common environmental factors causing cancer are tobacco (25–30%), diet and obesity (30–35%), infections (15–20%), radiation (both ionizing and nonionizing, up to 10%), stress, lack of physical activity, and environmental pollutant [2]. Death rates for cancer have continued to decline for both men and women of all racial and ethnic groups and have decreased by 1.5% per year from 2000–2009 for both sexes [3]. Trends in cancer death rates continue to decline; however, increase in incidence rates for some HPV associated cancer and low vaccination coverage among adolescents emphasize need for prevention in HPV associated cancer as well as to increase the coverage of vaccine. The development of new anticancer therapeutic agents is one of the fundamental goals in medicinal chemistry [4]. Medicinal chemists have great interest in research and development for the search of newer and safer anticancer agents. Epidermal growth factor receptor (EGFR) family of tyrosine kinase (TK) play a vital role in cancer proliferation and it is suggested that any agent would inhibit the TK activity and may have a considerable role in cancer treatment. N-containing heterocyclic specially 1,3,4-oxadiazole ring are of great interest for researchers as they are found in natural products and are used frequently in medicinal and pharmaceutical chemistry [5]. Oxadiazole has a furan ring with two methane (–CH=) groups and is replaced by two pyridine types of nitrogen (–N=) atoms. Four types of isomers are possible in oxadiazole nucleus depending on the position of nitrogen present in the ring [6]. (See Scheme 1).

Scheme 1

The heterocyclic compounds containing 1,3,4-oxadiazole moiety are used as piconjugation which is used to prepare a large number of biologically active molecules (donor-acceptor) that carry a pielectron in their aromatic ring. Therefore, the compounds containing 1,3,4-oxadiazole moiety may be a good choice for optical material or biologically active chemicals [7]. A large number of therapeutic agents like HIV-integrase inhibitor raltegravir [8], nitrofuran antibacterial furamizole [9], antihypertensive agents tiodazosin [10], and nesapidil [11] are based on 1,3,4-oxadiazole moiety. For the development of pharmaceutically active compound, researcher have explored various molecules containing 1,3,4-oxadiazole nucleus which have already been explored. The literature review reveals that the compounds having five-membered heterocyclic ring containing nitrogen and oxygen like 1,3,4-oxadiazole have been synthesized and have showed a variety of biological activities like anticancer [12–16], anticonvulsant [17–19], antimicrobial [20–25], anti-inflammatory analgesic [26–29], dyes and pigments [30], ulcerogenic [31], antitubercular activities [32]. Apart from that there are some natural analogues like curcumin and its derivative which have very good anticancer activity [33].

2. Material and Method

2.1. Chemistry

The chemicals used for experimental work were commercially procured from various chemical units, namely, E. Merck India Ltd., CDH and S.D. Fine chem. and Qualigens. These solvent and reagents were of LR grade and were purified before use. The silica gel G (160-120 mesh) used for analytical chromatography (TLC) was obtained from E. Merck India Ltd. The solvent system used was benzene : acetone (9 : 1) and (8 : 2) and toluene : ethyl acetate : formic acid (5 : 4 : 1). Ashless Whattman number 1 filter paper was used for vacuum filtration. Melting points were determined in open glass capillary using melting point apparatus and are uncorrected. The proton nuclear magnetic resonance (¹HNMR) spectra were recorded on Bruker 300 MHz instrument in DMSO-d₆/CDCl₃ using tetramethylsilane [(CH₃)₄Si] as internal standard. The infrared spectra of the compound were recorded in KBr on Perkin-Elmer FTIR Spectrometer, and the iodine chamber and U.V.-lamp were used for visualisation of TLC spots. Mass spectra were recorded on API 2000 LC/MS/MS system and elemental analyses were performed on Perkin-Elmer 2400. The commercially available grades of solvents and reagents were found to be of adequate purity. However, the presence of undesirable impurities and others was likely to be used for experimental work for purification.

2.2. Synthesis of 2-Chloroquinoline-3-carbaldehyde (2)

2-Chloroquinoline-3-carbaldehyde was synthesized from acetanilide via a Vilsmeier-Haack reaction or by traditional methods. To a solution of acetanilide (5 mmole) in dry DMF (15 mmole) at 0–5°C with stirring, phosphorous oxychloride (60 mmole) was added dropwise and the mixture was stirred at 80–90°C for time ranges between 4 and 15 hr. The mixture was poured into crushed ice and stirred well and the resulting solid substance was filtered, washed well with cold water, and dried. The compounds were purified by recrystallization from either ethyl acetate or acetonitrile. Yield 65%, yellow solid, m.p 146–148°C. IR (KBr) cm⁻¹: 2871 (CH–ArH), 1687 (C=O), 749 (C–Cl). ¹H-NMR (DMSO-d₆) δ ppm: 6.78 (t, 1H,  Hz, H-5), 6.89 (d, 1H,  Hz, H-8), 7.25 (d, 1H,  Hz, H-6), 7.70 (t, 1H, , H-7), 10.25 (s, 1H, CHO). MS : 191.01 (M⁺). Anal. Calc. for C₁₀H₆ClNO; C, 62.68; H, 3.16; Cl, 18.50; N, 7.31; O, 8.35; Found: C, 62.71; H, 3.18; Cl, 18.48; N, 7.33; O, 8.37. MS (M⁺) 191.

2.2.1. Synthesis of 2-Oxo-1,2-dihydroquinoline-3-carbaldehyde (3)

A suspension of aldehyde (5 mmol) in 70% acetic acid (50 mL) was heated under reflux for 4-5 h. The process of the reaction was checked by thin layer chromatography. Upon cooling the reaction mixture, a solid product precipitated, which was filtered, washed with water, and dried. Yield 90%. m.p. 300–304°C. IR (KBr) cm⁻¹: 3320 (NH), 1670 (C=O), 2923 (CH aromatic). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 7.21 (t, 1H,  Hz, H-7), 7.37 (d, 1H,  Hz, H-8), 7.61 (t, 1H,  Hz, H-6), 7.80 (d, 1H,  Hz, H-5), 8.23 (s, 1H, H-4), 10.25 (CHO), 12.23 (CONH); Anal calcd for C₁₀H₇NO₂: C 69.36, H 4.07, N 8.09 Found: C 69.13, H 3.99, N 7.93; MS (M⁺) 173.

2.2.2. Synthesis 2-(p-Tolyloxy)quinoline-3-carbaldehyde (4)

To a mixture of p-cresol (0.031 mmol) K₂CO₃ (0.068 mmol) in DMF, the 2-chloroquinoline-3-carbaldehyde (0.031 mmol) was added and the reaction mixture was stirred at 85–90°C for 5 h. The completion of reaction was monitored by TLC. After completion, water (50 mL) was poured in the reaction mixture and the solid thus obtained was filtered off and recrystallized from ethyl alcohol. Yield 76%; m.p. 126–128°C. IR (KBr) cm⁻¹: 2950 (CH, aromatic), 2670 (CH, aliphatic), 1720 (C=O); 1230 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.35 (s, 3H, CH₃), 7.05 (d, 2H,  Hz, ArH), 7.19 (d, 2H,  Hz, ArH), 7.31–7.69 (m, 3H, ArH), 7.77 (d, 2H,  Hz, ArH), 10.35 (s, 1H, CHO). Anal calcd for C₁₇H₁₃NO₂: C 77.55, H 4.98, N 5.32, O 12.15. Found C 77.58, H, 5.02, N 5.28, O 12.10; MS (M⁺) 263.

2.3. General Method for the Synthesis of 2-(2-Phenoxy/naphthyloxy-1H-benzimidazol-1-yl)-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]acetohydrazide (5-6)

A mixture of 2-[2-(phenoxy/naphthalen-2-yloxy methyl)-1H-benzimidazol-1-yl]acetohydrazide [12, 19] and 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (3) in ethanol was refluxed for 5 h. After completion of the reaction, the reaction mixture was concentrated, cooled, and poured in ice cold water, and the precipitate so formed was filtered, dried, and recrystallized to give the desired compound.

2.3.1. (2-Phenoxy Methyl-benzoimidazol-1-yl)-acetic acid (2-oxo-1,2-dihydro-quinolin-3-ylmethylene)-hydrazide (5)

Yield 73%, m.p. 296–299°C. IR (KBr) cm⁻¹: 3299 (NH), 2856 (CH, aromatic), 1647 (C=O), 1455 (N=CH), 1260 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 4.91 (s, 2H, CH₂), 5.31 (s, 2H, CH₂O), 7.17–7.24 (m, 3H, ArH), 7.33 (t, 3H,  Hz, ArH), 7.46 (t, 2H,  Hz, ArH), 7.62 (t, 2H,  Hz, ArH), 7.71–7.91 (m, 4H, ArH), 8.43 (N=CH), 10.24 (s, 1H, CH₂CONH), 12.12 (s, 1H, CONH quinoline). Anal calcd for C₂₆H₂₁N₅O₃: C 69.17, H 4.69, N 15.51, O 10.63. Found: C 69.11, H 4.73, N 15.54, O 10.59; MS (M⁺) 451.

2.3.2. [2-(Naphthalen-2-yloxymethyl)-benzoimidazol-1-yl]-acetic acid (2-oxo-1,2-dihydro-quinolin-3-ylmethylene)-hydrazide (6)

Yield 73%, m.p. 216–219°C. IR (KBr) cm⁻¹: 3170 (NH), 2871 (CH, aromatic), 1678 (C=O), 1447 (N=CH). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 4.95 (s, 2H, CH₂), 5.29 (s, 2H, CH₂O naphthyloxy), 7.12–7.21 (m, 4H, ArH), 7.32 (t, 3H,  Hz, ArH), 7.46 (t, 2H,  Hz, ArH), 7.59 (t, 2H,  Hz, ArH), 7.63–7.87 (m, 5H, ArH), 8.33 (N=CH), 10.21 (s, 1H, CH₂CONH), 12.22 (s, 1H, CONH quinoline). Anal calcd for C₃₀H₂₃N₅O₃: C 71.84, H 4.62, N 13.96, O 9.57. Found: C 71.87, H 4.59, N 13.95, O 9.57; MS (M⁺) 501.

2.4. General Method for the Synthesis of 3-[5-(2-Phenoxymethyl/naphthyloxy-benzoimidazol-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-quinolin-2-one (7, 8)

To an ethanolic solution of 2-(2-phenoxy/naphthyloxy-1H-benzimidazol-1-yl)-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]acetohydrazide (0.01 mole) (5-6) and chloramin-T (0.01 mole) was added. The solution was refluxed for 4 h, and sodium chloride which separated out during the course of reaction was filtered off. Excess ethanol was completely removed from the filtrate by distillation under reduced pressure, leaving behind a solid mass which was crystallized from ethanol to give the desired compound. Recrystallize the compounds from ethyl alcohol.

2.4.1. 3-[5-(2-Phenoxymethyl-benzoimidazol-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-quinolin-2-one (7)

Yield 58%. m.p. 252–255°C. IR (KBr) cm⁻¹: 3169 (NH), 2891 (CH, aromatic), 1667 (C=O), 1243 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 5.25 (s, 2H, CH₂), 5.51 (s, 2H, CH₂O), 6.91 (t, 1H,  Hz, ArH), 7.01 (d, 2H,  Hz ArH), 7.21–7.37 (m, 8H, ArH), 7.60–7.71 (m, 4H, ArH), 7.81 (d, 1H,  Hz, ArH), 12.47 (s, 1H, CONH). Anal calcd for C₂₆H₁₉N₅O₃: C 69.48, H 4.26, N 15.58, O 10.68. Found: C 69.51, H 4.21, N 15.52, O 10.69; MS (M⁺) 449.

2.4.2. 3-[5-(2-Naphthyloxymethyl-benzoimidazol-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-quinolin-2-one (8)

Yield 61%. m.p. 222–225°C. IR (KBr) cm⁻¹: 3172 (NH), 2890 (CH, aromatic), 1662 (C=O), 1244 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 5.22 (s, 2H, CH₂), 5.61 (s, 2H, CH₂O), 6.87 (t, 2H,  Hz, ArH), 7.03 (d, 2H,  Hz ArH), 7.20–7.36 (m, 9H, ArH), 7.49–7.78 (m, 4H, ArH), 7.84 (d, 1H,  Hz, ArH), 12.42 (s, 1H, CONH). Anal calcd for C₃₀H₂₁N₅O₃: C 72.13, H 4.24, N 14.02, O 9.61. Found: C 72.08, H 4.28, N 13.97, O 9.65; MS (M⁺) 499.

2.5. General Method for the Synthesis of 2-(Substituted)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]acetohydrazide (9–16)

A mixture of aromatic hydrazide [34] and 2-oxo-1,2-dihydroquinoline-3-carbaldehyde (3) in ethanol was refluxed for 5 h. After completion of the reaction, the reaction mixture was concentrated, cooled, and poured in ice cold water, and the precipitate so formed was filtered, dried, and recrystallized to give the desired compound.

2.5.1. 2-(Naphthalen-2-yloxy)-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]acetohydrazide (9)

Yield 64%. m.p. 236–239°C. IR (KBr) cm⁻¹: 3304 (NH), 2921 (CH, aromatic), 1666 (C=O), 1277 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 5.33 (s, 2H, CH₂O), 7.15–7.33 (m, 4H, ArH), 7.45 (d, 2H,  Hz, ArH), 7.83 (t, 2H,  Hz, ArH), 7.53–7.71 (m, 3H, ArH), 8.01 (s, 1H, ArH), 8.43 (s, 1H, N=CH), 10.54 (s, 1H, CH₂CONH), 11.89 (s, 1H, CONH quinoline). Anal calcd for C₂₃H₁₉N₃O₂: C 71.15, H 4.61, N 11.31, O 12.92. Found C 71.11, H 4.66, N 11.26, O 12.95; MS (M⁺) 385.

2.5.2. N′-[(E)-(2-Oxo-1,2-dihydroquinolin-3-yl)methylidene]-2-phenylacetohydrazide (10)

Yield 53%. m.p. 212–216°C. IR (KBr) cm⁻¹: 3274 (NH), 2923 (CH, aromatic), 1666 (C=O), 1500 (N=C), 1305 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 5.64 (s, 2H, OCH₂), 6.89 (s, 1H, ArH), 7.06 (d, 2H,  Hz, ArH), 7.33 (t, 4H,  Hz, ArH), 7.50–7.68 (m, 3H, ArH), 7.71–7.81 (m, 1H, ArH), 8.29 (s, 1H, N=CH), 8.48 (s, 1H, CH₂CONH), 11.81 (s, 1H, CONH quinoline). Anal calcd for C₁₈H₁₅N₃O₂: C 70.81, H 4.95, N 13.76, O 10.48. Found C 70.85, H 4.89, N 13.79, O 10.53; MS (M⁺) 319.

2.5.3. 4-Nitro-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]benzohydrazide (11)

Yield 57%. m.p. 294–298°C. IR (KBr) cm⁻¹: 3214 (NH), 2931 (CH, aromatic), 1670 (C=O), 1503 (N=C), 1303 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 7.05 (d, 2H,  Hz, ArH), 7.20–7.33 (m, 5H, ArH), 7.41 (t, 1H,  Hz, ArH), 7.78 (d, 2H,  Hz ArH), 8.37 (s, 1H, N=CH), 11.45 (s, 1H, CONH), 11.93 (s, 1H, CONH quinoline). Anal calcd for C₁₇H₁₂N₄O₄: C 60.71, H 3.60, N 16.66, O 19.03. Found: C 60.65, H 3.66, N 16.70, O 19.02; MS (M⁺) 350.

2.5.4. 4-Chloro-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]benzohydrazide (12)

Yield 57%. m.p. 284–286°C. IR (KBr) cm⁻¹: 3266 (NH), 2922 (CH, aromatic), 1670 (C=O), 1491 (N=C), 1311 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 7.19–7.23 (m, 2H, ArH), 7.32–7.35 (m, 2H, ArH), 7.51 (t, 2H,  Hz, ArH), 7.59 (d, 1H,  Hz, ArH), 7.84 (d, 2H,  Hz, ArH), 7.95 (d, 2H,  Hz, ArH), 8.47 (s, 1H, N=CH), 8.71 (s, 1H, CONH), 12.02 (s, 1H, CONH quinoline). Anal calcd for C₁₇H₁₂ClN₃O₂: C 62.68, H 3.71, Cl 10.88, N 12.90, O 9.82. Found: C 62.72, H 3.75, Cl 10.91, N 12.93, O 9.85; MS (M⁺) 339.

2.5.5. N′-[(E)-(2-Oxo-1,2-dihydroquinolin-3-yl)methylidene]pyridine-3-carbohydrazide (13)

Yield 57%. m.p. 268-269°C. IR (KBr) cm⁻¹: 3305 (NH), 2922 (CH, aromatic), 1604 (C=O), 1513 (N=C), 1277 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 7.14–7.50 (m, 6H, ArH), 7.70 (d, 2H,  Hz, ArH), 7.92 (t, 1H,  Hz, ArH), 8.66 (s, 1H, N=CH), 10.24 (s, 1H, CONH), 11.71 (s, 1H, CONH quinoline). Anal calcd for C₁₆H₁₂N₄O₂: C 65.75, H 4.14, N 19.17, O 10.95. Found: C 65.70, H 4.17, N 19.17, O 10.99; MS (M⁺) 306.

2.5.6. N′-[(E)-(2-Oxo-1,2-dihydroquinolin-3-yl)methylidene]-2-phenoxyacetohydrazide (14)

Yield 67%. m.p. 85–88°C. IR (KBr) cm⁻¹: 3255 (NH), 2945 (CH, aromatic), 1634 (C=O), 1500 (N=C), 1306 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 4.46 (s, 2H, OCH₂), 7.31–7.37 (t, 4H,  Hz, ArH), 7.38 (s, 1H, aromatic), 7.48–7.61 (m, 5H, ArH), 8.30 (s, 1H, N=CH), 10.31 (s, 1H, CONH), 11.29 (s, 1H, CONH quinoline). Anal calcd for C₁₆H₁₂N₄O₂: C 67.28, H 4.71, N 13.08, O 14.94. Found: C 67.32, H 4.69, N 13.02, O 14.97; MS (M⁺) 306.

2.5.7. 3,5-Dinitro-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]benzohydrazide (15)

Yield 72%. m.p. 270–272°C. IR (KBr) cm⁻¹: 3311 (NH), 2931 (CH, aromatic), 1663 (C=O), 1500 (N=C), 1309 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 6.96 (t, 2H,  Hz, ArH), 7.14–7.34 (m, 3H. ArH), 7.50 (d, 1H,  Hz, ArH), 7.75 (d, 1H,  Hz, ArH), 8.20 (s, 1H, ArH), 8.58 (s, 1H, N=CH), 11.67 (s, 1H, CONH), 11.98 (s, 1H, CONH quinoline). Anal calcd for C₁₇H₁₁N₅O₆: C 53.55, H 2.91, N 18.37, O 25.18. Found: C 53.50, H 2.94, N 18.39, O 25.18; MS (M⁺) 380.

2.5.8. 2-Hydroxy-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]benzohydrazide (16)

Yield 71%. m.p. 149–151°C. IR (KBr) cm⁻¹: 3307 (NH), 2930 (CH, aromatic), 1634 (C=O), 1500 (N=C), 1308 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 6.88 (m, 2H, ArH), 7.23 (t, 1H,  Hz, ArH), 7.33 (d, 1H,  Hz. ArH), 7.46 (t, 2H,  Hz, ArH), 7.61 (t, 1H,  Hz, ArH), 7.76 (d, 1H,  Hz, ArH), 7.89 (d, 1H,  Hz, ArH), 8.49 (s, 1H, N=CH), 10.22 (s, 1H, OH), 11.29 (s, 1H, CONH), 12.22 (s, 1H, CONH quinoline). Anal calcd for C₁₇H₁₃N₃O₃: C 66.44, H 4.26, N 13.67, O 15.62. Found: C 66.47, H 4.31, N 13.74, O 15.65; MS (M⁺) 321.

2.6. General Method for the Synthesis of 3-(5-Substituted-1,3,4-oxadiazol-2-yl)quinolin-2(1H)-one (17–24)

To an ethanolic solution of 2-(substituted)-(2-oxo-1,2-dihydroquinolin-3-yl)methylideneacetohydrazide (0.01 mole) (9-16) and chloramin-T (0.01 mole) was added. The solution was refluxed for 4 h, and sodium chloride which separated out during the course of reaction was filtered off. Excess ethanol was completely removed from the filtrate by distillation under reduced pressure, leaving behind a solid mass which was crystallized from ethanol to give the desired compound. Recrystallize from ethyl alcohol.

2.6.1. 3-{5-[(Naphthalen-2-yloxy)methyl]-1,3,4-oxadiazol-2-yl}quinolin-2(1H)-one (17)

Yield 61%. m.p. 116–124°C. IR (KBr) cm⁻¹: 3317 (NH), 2934 (CH, aromatic), 1636 (C=O), 1441 (N=C), 1333 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 5.22 (s, 2H, OCH₂), 7.34 (D, 2H,  Hz, ArH), 7.40–7.63 (m, 8H, ArH), 7.68 (d, 1H,  Hz, ArH), 11.23 (s, 1H, CONH). Anal calcd for C₂₂H₁₅N₃O₂: C 74.78, H 4.28, N 11.89, O 9.06. Found: C 74.77, H 4.31, N 11.84, O 9.06; MS (M⁺) 369.

2.6.2. 3-(5-Benzyl-1,3,4-oxadiazol-2-yl)quinolin-2(1H)-one (18)

Yield 64%. m.p. 189-190°C. IR (KBr) cm⁻¹: 3382 (NH), 2904 (CH, aromatic), 1656 (C=O), 1435 (N=C), 1305 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 4.36 (s, 2H, CH₂), 7.27 (t, 5H,  Hz, ArH), 7.46–7.70 (m, 3H, ArH), 7.79–7.91 (m, 2H, ArH), 12.17 (s, 1H, CONH). Anal calcd for C₁₈H₁₃N₃O₂: C 71.28, H 4.32, N 13.85, O 10.55. Found: C 71.23, H 4.37, N 13.85, O 10.59; MS (M⁺) 303.

2.6.3. 3-[5-(4-Nitrophenyl)-1,3,4-oxadiazol-2-yl]quinolin-2(1H)-one (19)

Yield 54%. m.p. 223–225°C. IR (KBr) cm⁻¹: 3304 (NH), 2932 (CH, aromatic), 1665 (C=O), 1502 (N=C), 1304 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 6.46 (t, 1H,  Hz, ArH), 7.00–7.38 (m, 3H, ArH), 7.50–7.93 (m, 5H, ArH), 12.17 (s, 1H, CONH). Anal calcd for C₁₇H₁₀N₄O₄: C 61.08, H 3.02, N 16.06, O 19.14. Found: C 61.13, H 3.08, N 16.04, O 19.11; MS (M⁺) 348.

2.6.4. 3-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]quinolin-2(1H)-one (20)

Yield 54%. m.p. 256–260°C. IR (KBr) cm⁻¹: 3300 (NH), 2903 (CH, aromatic), 1650 (C=O), 1505 (N=C), 1310 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 7.62–7.73 (m, 6H, ArH), 7.91 (t, 2H,  Hz, ArH), 8.09 (d, 1H,  Hz, ArH), 12.27 (s, 1H, CONH). Anal calcd for C₁₇H₁₀ClN₃O₂: C 63.07, H 3.11, Cl 10.95, N 12.98, O 9.88. Found: C 63.11, H 3.05, Cl 10.99, N 13.04, O 9.85; MS (M⁺) 337.

2.6.5. 3-[5-(Pyridin-3-yl)-1,3,4-oxadiazol-2-yl]quinolin-2(1H)-one (21)

Yield 67%. m.p. 168-169°C. IR (KBr) cm⁻¹: 3159 (NH), 2971 (CH, aromatic), 1658 (C=O), 1491 (N=C), 1331 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 7.17 (t, 2H, .1 Hz, ArH), 7.27 (d, 2H,  Hz, ArH), 7.48 (t, 2H,  Hz, ArH), 7.72 (d, 2H,  Hz, ArH), 7.93 (s, 1H, ArH), 11.82 (s, 1H, CONH). Anal calcd for C₁₆H₁₀N₄O₂: C 66.20, H 3.47, N 19.30, O 11.02. Found: C 66.23, H 3.41, N 19.33, O 11.06; MS (M⁺) 304.

2.6.6. 3-[5-(Phenoxymethyl)-1,3,4-oxadiazol-2-yl]quinolin-2(1H)-one (22)

Yield 67%. m.p. 137–140°C. IR (KBr) cm⁻¹: 3090 (NH), 2915 (CH, aromatic), 1655 (C=O), 1429 (N=C), 1303 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 5.23 (s, 2H, CH₂O), 7.07 (t, 2H,  Hz, ArH), 7.27–7.46 (m, 5H, ArH), 7.74 (d, 2H,  Hz, ArH), 7.89 (s, 1H, ArH), 11.87 (s, 1H, CONH). Anal calcd for C₁₈H₁₃N₃O₃: C 67.71, H 4.10, N 13.16, O 15.03. Found: C 67.75, H 4.13, N 13.21, O 15.01; MS (M⁺) 319.

2.6.7. 3-[5-(3,5-Dinitrophenyl)-1,3,4-oxadiazol-2-yl]quinolin-2(1H)-one (23)

Yield 67%. m.p. 275–277°C. IR (KBr) cm⁻¹: 3290 (NH), 2916 (CH, aromatic), 1665 (C=O), 1432 (N=C), 1305 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 7.27–7.39 (m, 3H, ArH), 7.54 (t, 2H,  Hz, ArH), 7.81 (d, 2H,  Hz, ArH), 8.01 (s, 1H, ArH), 11.58 (s, 1H, CONH). Anal calcd for C₁₇H₉N₅O₆: C 53.86, H 2.39, N 18.46, O 25.31. Found: C 53.87, H 2.42, N 18.47, O 25.35; MS (M⁺) 379.

2.6.8. 3-[5-(2-Hydroxyphenyl)-1,3,4-oxadiazol-2-yl]quinolin-2(1H)-one (24)

Yield 74%. m.p. 288–290°C. IR (KBr) cm⁻¹: 3307 (NH), 3167 (OH), 2936 (CH, aromatic), 1668 (C=O), 1432 (N=C), 1303 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 6.88–6.94 (m, 3H, ArH), 7.13 (t, 2H,  Hz, ArH), 7.30 (d, 2H,  Hz, ArH), 7.43–7.51 (m, 4H, ArH), 7.60 (d, 1H,  Hz, ArH), 10.31 (s, 1H, OH), 12.23 (s, 1H, CONH). Anal calcd for C₁₇H₁₁N₃O₃: C 66.68, H 3.63, N 13.76, O 15.72. Found: C 66.61, H 3.68, N 13.79, O 15.65; MS (M⁺) 305.

2.7. General Method for the Synthesis of 2-(2-Phenoxymethyl/naphthyloxymethyl-1H-benzimidazol-1-yl)-acetic acid (2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (25-26)

A mixture of 2-[2-(phenoxy/naphthalen-2-yloxy methyl)-1H-benzimidazol-1-yl]acetohydrazide [12, 19] and 2-(p-tolyloxy)quioline-3-carbaldehyde (4) in ethanol was refluxed for 5 h. After completion of the reaction, the reaction mixture was concentrated, cooled, and poured in ice cold water, and the precipitate so formed was filtered, dried, and recrystallized to give the desired compound.

2.7.1. (2-Phenoxy methyl-benzimidazol-1-yl)-acetic acid (2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (25)

Yield 68%, m.p. 126–129°C. IR (KBr) cm⁻¹: 3299 (NH), 2855 (CH, aromatic), 1665 (C=O), 1451 (N=CH), 1266 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.37 (s, 3H, CH₃), 5.47 (s, 2H, CH₂), 5.62 (s, 2H, CH₂O), 6.92 (t, 2H,  Hz, ArH), 7.03 (d, 3H,  Hz, ArH), 7.12–7.36 (m, 4H, ArH), 7.45 (t, 3H,  Hz, ArH), 7.54–7.63 (m, 2H, ArH), 7.73–7.92 (m, 4H, ArH), 8.28 (N=CH), 9.84 (s, 1H, CH₂CONH). Anal calcd for C₃₃H₂₇N₅O₃: C 73.18, H 5.02, N 12.93, O 8.86. Found: C 73.12, H 5.04, N 12.96, O 8.89; MS (M⁺) 591.

2.7.2. (2-Naphthyloxymethyl-benzimidazol-1-yl)-acetic acid (2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (26)

Yield 68%, m.p. 224–226°C. IR (KBr) cm⁻¹: 3294 (NH), 2844 (CH, aromatic), 1684 (C=O), 1449 (N=CH), 1268 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.34 (s, 3H, CH₃), 5.34 (s, 2H, CH₂), 5.77 (s, 2H, CH₂O), 6.94 (t, 3H,  Hz, ArH), 7.08 (d, 3H,  Hz, ArH), 7.11–7.35 (m, 4H, ArH), 7.43 (t, 3H,  Hz, ArH), 7.47–7.60 (m, 3H, ArH), 7.67–7.86 (m, 4H, ArH), 8.34 (N=CH), 10.84 (s, 1H, CH₂CONH). Anal calcd for C₃₇H₂₉N₅O₃: C 75.11, H 4.94, N 11.84, O 8.11. Found: C 75.15, H 4.97, N 11.80, O 8.12; MS (M⁺) 541.

2.8. General Method for the Synthesis of 3-[5-(2-Phenoxymethyl/naphthyloxymethyl-benzoimidazol-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-2-p-tolyloxy-quinoline (27-28)

To an ethanolic solution of 2-(2-phenoxymethyl/naphthyloxymethyl-1H-benzimidazol-1-yl)-acetic acid (2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (0.01 mole) (25-26) and chloramin-T (0.01 mole) was added. The solution was refluxed for 4 h, and sodium chloride which separated out during the course of reaction was filtered off. Excess ethanol was completely removed from the filtrate by distillation under reduced pressure, leaving behind a solid mass which was crystallized from ethanol to give the desired compound. Recrystallize from ethyl alcohol.

2.8.1. 3-[5-(2-Phenoxymethyl-benzoimidazol-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-2-p-tolyloxy-quinoline (27)

Yield 68%. m.p. 80–84°C. IR (KBr) cm⁻¹: 3202 (NH), 2799 (CH, aromatic), 1677 (C=O), 1405 (C=N), 1245 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.34 (s, 3H, CH₃), 5.48 (s, 2H, CH₂), 6.07 (s, 2H, CH₂O), 6.86–7.09 (m, 3H, ArH), 7.21 (d, 7H,  Hz ArH), 7.45–7.69 (m, 4H, ArH), 7.72 (t, 3H,  Hz, ArH), 8.14 (s, 1H, ArH). Anal calcd for C₃₃H₂₅N₅O₃: C 73.46, H 4.67, N 12.98, O 8.90. Found: C 73.49, H 4.62, N 12.94, O 8.96; MS (M⁺) 539.

2.8.2. 3-[5-(2-Naphthyloxy-methyl-benzoimidazol-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-2-p-tolyloxy-quinoline (28)

Yield 68%. m.p. 212–215°C. IR (KBr) cm⁻¹: 3210 (NH), 2791 (CH, aromatic), 1674 (C=O), 1407 (C=N), 1249 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.31 (s, 3H, CH₃), 5.34 (s, 2H, CH₂), 5.94 (s, 2H, CH₂O), 6.82–7.11 (m, 4H, ArH), 7.18 (d, 7H,  Hz ArH), 7.38–7.71 (m, 5H, ArH), 7.77 (t, 3H,  Hz, ArH), 8.04 (s, 1H, ArH). Anal calcd for C₃₇H₂₇N₅O₃: C 75.37, H 4.62, N 11.88, O 8.14. Found: C 75.40, H 4.57, N 11.93, O 8.17; MS (M⁺) 589.

2.9. General Method for the Synthesis of Substituted-(2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (29–36)

A mixture of aromatic hydrazide [34] and 2-(p-tolyloxy)quioline-3-carbaldehyde (4) in ethanol was refluxed for 5 h. After completion of the reaction, the reaction mixture was concentrated, cooled, and poured in ice cold water, and the precipitate so formed was filtered, dried, and recrystallized to give the desired compound.

2.9.1. (Naphthalen-2-yloxy)-acetic acid (2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (29)

Yield 64%. m.p. 226-227°C. IR (KBr) cm⁻¹: 3298 (NH), 2923 (CH, aromatic), 1667 (C=O), 1455 (C=N), 1277 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.36 (s, 3H, CH₃), 4.83 (s, 2H, OCH₂), 7.15–7.37 (d, 4H,  Hz, ArH), 7.48 (d, 4H,  Hz, ArH), 7.57–7.68 (m, 4H, ArH), 7.82 (t, 4H,  Hz, ArH), 8.53 (s, 1H, N=CH), 11.82 (s, 1H, CH₂CONH). Anal calcd for C₂₉H₂₃N₃O₃: C 75.47, H 5.02, N 9.10, O 10.40. Found C 75.49, H 5.08, N 9.14, O 10.45; MS (M⁺) 461.

2.9.2. Phenylacetic acid (2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (30)

Yield 64%. m.p. 228-229°C. IR (KBr) cm⁻¹: 3290 (NH), 2917 (CH, aromatic), 1666 (C=O), 1458 (C=N), 1260 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.32 (s, 3H, CH₃), 4.08 (s, 2H, CH₂), 7.02 (d, 2H,  Hz, ArH), 7.14–7.32 (m, 5H, ArH), 7.51–7.60 (m, 2H, ArH), 7.46 (t, 1H,  Hz, ArH), 8.34 (s, 1H, N=CH), 10.61 (s, 1H, CH₂CONH). Anal calcd for C₂₅H₂₁N₃O₂: C 75.93, H 5.35, N 10.63, O 8.09. Found C 75.99, H 5.37, N 10.63, O 8.03; MS (M⁺) 395.

2.9.3. N′-(E)-[2-(4-Methylphenoxy)quinolin-3-yl]methylidene-4-nitrobenzohydrazide (31)

Yield 64%. m.p. 151–153°C. IR (KBr) cm⁻¹: 3293 (NH), 2927 (CH, aromatic), 1664 (C=O), 1457 (C=N), 1263 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 3.79 (s, 3H, CH₃), 7.17–7.29 (m, 4H, ArH), 7.50–7.64 (m, 3H, ArH), 8.10 (d, 2H,  Hz, ArH), 8.19 (d, 2H, ArH), 8.36 (d, 2H,  Hz, ArH), 8.91 (s, 1H, N=CH), 12.39 (s, 1H, CONH). Anal calcd for C₂₄H₁₈N₄O₄: C 67.60, H 4.25, N 13.14, O 15.01. Found C 67.63, H 4.29, N 13.19, O 15.00; MS (M⁺) 426.

2.9.4. 4-Chlorobenzoic acid (2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (32)

Yield 67%. m.p. 244-245°C. IR (KBr) cm⁻¹: 3198 (NH), 2908 (CH, aromatic), 1667 (C=O), 1460 (C=N), 1261 (C–O), 728 (Cl). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.36 (s, 3H, CH₃), 7.16 (d, 2H,  Hz, ArH), 7.26 (d, 2H,  Hz, ArH), 7.49 (t, 2H,  Hz, ArH), 7.59–7.69 (m, 4H, ArH), 7.98 (d, 2H,  Hz, ArH), 8.07 (s, 1H, ArH), 8.72 (s, 1H, N=CH), 12.07 (s, 1H, CONH). Anal calcd for C₂₄H₁₈ClN₃O₂: C 69.31, H 4.36, Cl 10.10, N 10.10, O 7.69. Found C 69.35, H 4.41, Cl 10.13, N 10.05, O 7.75; MS (M⁺) 415.

2.9.5. N′-(E)-[2-(4-Methylphenoxy)quinolin-3-yl]methylidenepyridine-3-carbohydrazide (33)

Yield 71%. m.p. 88–90°C. IR (KBr) cm⁻¹: 3298 (NH), 2913 (CH, aromatic), 1665 (C=O), 1467 (C=N), 1256 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 3.27 (s, 3H, CH₃), 7.10 (d, 2H,  Hz, ArH), 7.19 (d, 2H,  Hz, ArH), 7.45–7.69 (m, 3H, ArH), 7.72 (t, 3H,  Hz, ArH), 8.04 (d, 2H,  Hz, ArH), 8.15 (s, 1H, ArH), 8.76 (s, 1H, N=CH), 10.49 (s, 1H, CONH). Anal calcd for C₂₃H₁₈N₄O₂: C 72.24, H 4.74, N 14.65, O 8.37. Found C 72.27, H 4.70, N 14.70, O 8.41; MS (M⁺) 382.

2.9.6. N′-(E)-[2-(4-Methylphenoxy)quinolin-3-yl]methylidenephenoxymethyl-3-carbohydrazide (34)

Yield 71%. m.p. 188–190°C. IR (KBr) cm⁻¹: 3245 (NH), 2879 (CH, aromatic), 1670 (C=O), 1463 (C=N), 1259 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.35 (s, 3H, CH₃), 5.24 (s, 2H, OCH₂), 6.95 (d, 3H,  Hz, ArH), 7.14 (d, 2H,  Hz, ArH), 7.25 (d, 3H,  Hz, ArH), 7.48–7.65 (m, 4H, ArH), 8.00–8.09 (m, 1H, ArH), 8.49 (s, 1H, ArH), 8.87 (s, 1H, N=CH), 11.84 (s, 1H, CH₂CONH). Anal calcd for C₂₅H₂₁N₃O₂: C 72.98, H 5.14, N 10.21, O 11.67. Found C 72.94, H 5.09, N 10.25, O 11.72; MS (M⁺) 411.

2.9.7. N′-(E)-[2-(4-Methylphenoxy)quinolin-3-yl]methylidene-3,5-dinitrophenyl-3-carbohydrazide (35)

Yield 75%. m.p. 70–72°C. IR (KBr) cm⁻¹: 3278 (NH), 2887 (CH, aromatic), 1673 (C=O), 1465 (C=N), 1262 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.37 (s, 3H, CH₃), 6.93 (d, 2H,  Hz, ArH), 7.15 (d, 2H,  Hz, ArH), 7.25 (d, 2H,  Hz, ArH), 7.47–7.68 (m, 4H, ArH), 8.00–8.07 (m, 1H, ArH), 8.11 (s, 1H, ArH), 8.47 (s, 1H, N=CH), 12.14 (s, 1H, CONH). Anal calcd for C₂₄H₁₇N₅O₅: C 61.15, H 3.63, N 14.86, O 20.36. Found C 61.11, H 3.67, N 14.81, O 20.31; MS (M⁺) 471.

2.9.8. 2-Hydroxy-N′-(E)-[2-(4-methylphenoxy)quinolin-3-yl]methylidenebenzohydrazide (36)

Yield 74%. m.p. 215-216°C. IR (KBr) cm⁻¹: 3316 (OH), 3290 (NH), 2887 (CH, aromatic), 1672 (C=O), 1454 (C=N), 1265 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.35 (s, 3H, CH₃), 6.87–6.94 (m, 1H, ArH), 7.18–7.28 (m, 5H, ArH), 7.46–7.55 (m, 3H, ArH), 7.60 (d, 2H,  Hz, ArH), 7.76 (t, 2H,  Hz, ArH), 8.15 (s, 1H, N=CH), 8.84 (s, 1H, OH), 10.48 (s, 1H, CONH). Anal calcd for C₂₄H₁₇N₅O₅: C 61.15, H 3.63, N 14.86, O 20.36. Found C 61.11, H 3.67, N 14.81, O 20.31; MS (M⁺) 397.

2.10. General Method for the Synthesis of 2-(4-Methylphenoxy)-3-(5-substituted-1,3,4-oxadiazol-2-yl)quinoline (37–44)

To an ethanolic solution of substituted-(2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide (0.01 mole) (29-36) and chloramin-T (0.01 mole) was added. The solution was refluxed for 4 h, and sodium chloride which separated out during the course of reaction was filtered off. Excess ethanol was completely removed from the filtrate by distillation under reduced pressure, leaving behind a solid mass which was crystallized from ethanol to give the desired compound. Recrystallize from ethyl alcohol.

2.10.1. 3-[5-(Naphthalen-2-yloxymethyl)-[1,3,4]oxadiazol-2-yl]-2-p-tolyloxy-quinoline (37)

Yield 65%. m.p. 115-116°C. IR (KBr) cm⁻¹: 2875 (CH, aromatic), 1498 (N=C), 1238 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.40 (s, 3H, CH₃), 5.52 (s, 2H, OCH₂), 7.28–7.50 (m, 5H, ArH), 7.67 (d, 6H,  Hz, ArH), 7.82 (t, 3H,  Hz, ArH), 7.88 (d, 2H,  Hz). Anal calcd for C₂₉H₂₁N₃O₃: C 75.80, H 4.61, N 9.14, O 10.45. Found: C 75.85, H 4.57, N 9.19, O 10.38; MS (M⁺) 459.

2.10.2. 3-(5-Benzyl-1,3,4-oxadiazol-2-yl)-2-(4-methylphenoxy)quinoline (38)

Yield 54%. m.p. 147-148°C. IR (KBr) cm⁻¹: 2972 (CH, aromatic), 1462 (N=C), 1237 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.43 (s, 3H, ArH), 4.32 (s, 2H, CH₂), 7.19 (d, 3H,  Hz, ArH), 7.26 (d, 3H,  Hz, ArH), 7.47 (t, 2H,  Hz, ArH), 7.68–7.77 (m, 3H, ArH), 7.89 (d, 2H,  Hz, ArH). Anal calcd for C₂₅H₁₉N₃O₂: C 76.32, H 4.87, N 10.68, O 8.13. Found: C 76.27, H 4.91, N 10.71, O 8.12; MS (M⁺) 393.

2.10.3. 2-(4-Methylphenoxy)-3-[5-(4-nitrophenyl)-1,3,4-oxadiazol-2-yl]quinoline (39)

Yield 57%. m.p. 85–88°C. IR (KBr) cm⁻¹: 2867 (CH, aromatic), 1509 (N=C), 1341 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 6.42 (t, 1H,  Hz, ArH), 7.02–7.35 (m, 5H, ArH), 7.47–7.67 (m, 3H, ArH), 7.72 (t, 1H,  Hz, ArH), 7.83 (d, 2H,  Hz, ArH). Anal calcd for C₂₄H₁₆N₄O₄: C 67.92, H 3.80, N 13.20, O 15.08. Found: C 67.97, H 3.78, N 13.23, O 15.04; MS (M⁺) 424.

2.10.4. 3-[5-(4-Chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-(4-methylphenoxy)quinoline (40)

Yield 56%. m.p. 127–131°C. IR (KBr) cm⁻¹: 2867 (CH, aromatic), 1509 (N=C), 1255 (C–O), 756 (C–Cl). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.34 (s, 3H, CH₃) 7.18 (d, 2H,  Hz, ArH), 7.25 (d, 2H,  Hz, ArH), 7.52 (t, 2H,  Hz, ArH), 7.59 (d, 2H,  Hz, ArH), 7.73 (d, 2H,  Hz, ArH), 8.11 (d, 2H,  Hz, ArH), 8.47 (s, 1H, ArH). Anal calcd for C₂₄H₁₆ClN₃O₂: C 69.65, H 3.90, Cl 8.57, N 10.15, O 7.33. Found: C 69.62, H 3.93, Cl 8.56, N 10.11, O 7.27; MS (M⁺) 413.

2.10.5. 2-(4-Methylphenoxy)-3-[5-(pyridin-3-yl)-1,3,4-oxadiazol-2-yl]quinoline (41)

Yield 64%. m.p. 182–184°C. IR (KBr) cm⁻¹: 2871 (CH, aromatic), 1444 (N=C), 1231 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 3.27 (s, 3H, CH₃), 7.12 (d, 2H,  Hz, ArH), 7.21 (d, 2H,  Hz, ArH), 7.44–7.64 (m, 3H, ArH), 7.75 (t, 3H,  Hz, ArH), 8.01 (d, 2H,  Hz, ArH), 8.07 (s, 1H, ArH). Anal calcd for C₂₃H₁₆N₄O₂: C 72.62, H 4.24, N 14.73, O 8.41. Found: C 72.56, H 4.27, N 14.68, O 8.46; MS (M⁺) 380.

2.10.6. 2-(4-Methylphenoxy)-3-[5-(phenoxymethyl)-1,3,4-oxadiazol-2-yl]quinoline (42)

Yield 77%. m.p. 99–102°C. IR (KBr) cm⁻¹: 3358 (OH), 2865 (CH, aromatic), 1404 (N=C), 1305 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.40 (s, 3H, CH₃), 4.47 (s, 2H, CH₂O), 7.14 (d, 2H,  Hz, ArH), 7.21–7.31 (m, 5H, ArH), 7.38 (d, 2H,  Hz, ArH), 7.47 (t, 2H,  Hz, ArH), 7.55 (d, 2H,  Hz, ArH), 7.79 (d, 2H,  Hz, ArH), 7.89 (s, 1H, ArH). Anal calcd for C₂₅H₁₉N₃O₃: C 73.34, H 4.68, N 10.26, O 11.72. Found: C 73.29, H 4.71, N 10.31, O 11.77; MS (M⁺) 409.

2.10.7. 3-[5-(3,5-Dinitrophenyl)-1,3,4-oxadiazol-2-yl]-2-(4-methylphenoxy)quinoline (43)

Yield 65%. m.p. 206–209°C. IR (KBr) cm⁻¹: 2887 (CH, aromatic), 1465 (C=N), 1262 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.33 (s, 3H, CH₃), 6.97 (d, 2H,  Hz, ArH), 7.05 (d, 2H,  Hz, ArH), 7.22 (d, 2H,  Hz, ArH), 7.41–7.58 (m, 4H, ArH), 7.79–7.95 (m, 2H, ArH). Anal calcd for C₂₄H₁₅N₅O₆: C 61.41, H 3.22, N 14.92, O 20.45. Found C 61.37, H 3.22, N 14.91, O 20.44; MS (M⁺); MS (M⁺) 469.

2.10.8. 2-5-[2-(4-Methylphenoxy)quinolin-3-yl]-1,3,4-oxadiazol-2-ylphenol (44)

Yield 74%. m.p. 145-146°C. IR (KBr) cm⁻¹: 3178 (OH), 2922 (CH, aromatic), 1662 (C=O), 1440 (N=C), 1276 (C–O). ¹H-NMR (300 MHz DMSO-d₆) δ ppm: 2.34 (s, 3H, CH₃), 7.07 (d, 2H,  Hz, ArH), 7.19–7.36 (m, 5H, ArH), 7.44 (d, 2H,  Hz, ArH), 7.52 (t, 2H,  Hz, ArH), 7.68 (d, 1H,  Hz, ArH), 7.75 (d, 1H,  Hz, ArH), 7.99 (d, 1H,  Hz, ArH). Anal calcd for C₂₄H₁₇N₃O₃: C 72.90, H 4.33, N 10.63, O 12.14. Found: C 72.95, H 4.37, N 10.64, O 12.17, MS (M⁺) 395.

2.11. Anticancer Activity [35–40]

There were eleven compounds of the series, selected and screened for their anticancer activity for one-dose assay and among that two compounds were selected for 5-dose assay, after one-dose assay done by the National Cancer Institute (NCI) on leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate, and breast cancers cell lines, nearly 60 in number according to their screening protocol. All the synthesised compounds and structure of the compounds were submitted online to the official site of NCI for anticancer screening. Among 24 compounds only 11 compounds were selected for anticancer screening. NCI has its own selection procedure of the compounds for anticancer screening based on the novelty of heterocyclic ring system, drug-like properties utilizing the concept of privileged scaffolds, structure based on computer-aided drug design, and so forth, while the chemical structures containing some problematic linkages or functional groups. The anticancer screening was carried out as per the NCI US protocol. All compounds submitted to the NCI 60 Cell screen were tested initially at a single high dose (10⁻⁵ M) on leukemia, melanoma, lung, colon, CNS, ovarian, renal, prostate, and breast cancers cell lines, nearly 60 in number. The one-dose assay data was reported as a mean graph of the percent growth of treated cells. The number reported for the one-dose assay is the growth relative to the no-drug control and relative to the time zero number of cells. Using the absorbance measurements (time zero (Tz), control growth (C), and test growth in the presence of drug at the five concentration levels (Ti)) the percentage growth was calculated at each of the drug concentration levels.

Percentage growth inhibition is calculated as follows:

 [(Ti − Tz)/(C − Tz)] × 100 for concentrations for which Ti ≥ Tz. [(Ti − Tz)/Tz] × 100 for concentrations for which Ti < Tz.

Three dose response parameters are calculated for each experimental agent. The growth inhibition of 50% (GI50) is calculated from [(Ti − Tz)/(C − Tz)] × 100 = 50, which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation. The drug concentration resulting in total growth inhibition (TGI) is calculated from Ti = Tz. The LC50 (concentration of drug resulting in a 50% reduction in the measured protein at the end of the drug treatment as compared to that at the beginning) indicating a net loss of cells following treatment is calculated from [(Ti − Tz)/Tz] × 100 = −50. Values are calculated for each of these three parameters if the level of activity is reached; however, if the effect is not reached or is exceeded, the value for that parameter is expressed as greater or less than the maximum or minimum concentration tested or if the effect exceeded the level of activity, the value of parameter was expressed as greater than the maximum concentration tested. Log GI50, log TGI, and log LC50 are the logarithm molar concentrations producing 50% growth inhibition (GI50), a total growth inhibition (TGI), and a 50% cellular death (LC50), respectively.

3. Result and Discussion

3.1. Chemistry

2-Chloroquinoline-3-carbaldehyde 2 was prepared from acetanilide via Vilsmeier-Haack approach. 2-Oxo-1,2-dihydroquinoline-3-carbaldehyde 2 has been prepared in the presence of 70% acetic acid, and 2-(p-tolyloxy)quioline-3-carbaldehyde 4 was prepared from 2 by using -cresol and K₂CO₃ in the presence of DMF. In the step 1, 2-(2-phenoxy/naphthyloxy-1H-benzimidazol-1-yl)-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]acetohydrazide 5, 6 have been prepared with the help of 2-[2-(phenoxy/naphthalen-2-yloxy methyl)-1H-benzimidazol-1-yl]acetohydrazide. The 3-[5-(2-Phenoxymethyl/naphthyloxy-benzoimidazol-1-ylmethyl)-[1,3,4]oxadiazol-2-yl]-1H-quinolin-2-one 7, 8 were prepared by using 2-(2-phenoxy/naphthyloxy-1H-benzimidazol-1-yl)-N′-[(E)-(2-oxo-1,2-dihydroquinolin-3-yl)methylidene]acetohydrazide and chloramine-T. In the step 2 the 2-(substituted)-(2-oxo-1,2-dihydroquinolin-3-yl)methylideneacetohydrazide 9-16 have been prepared by 1,2-dihydroquinoline and substituted aromatic hydrazide. The corresponding 1,3,4-oxadiazole 17–24 has been synthesised by chloramine-T and ethyl alcohol. 2-(2-Phenoxymethyl/naphthyloxymethyl-1H-benzimidazol-1-yl)-acetic acid (2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide 25-26 have been synthesised from 2-[2-(phenoxy/naphthalen-2-yloxy methyl)-1H-benzimidazol-1-yl]acetohydrazide and 2-(p-tolyloxy)quioline-3-carbaldehyde 4 and the corresponding 1,3,4-oxadiazole 27-28 have also been synthesised by using chloramine-T. Further substituted-(2-p-tolyloxy-quinolin-3-ylmethylene)-hydrazide 29–37 were synthesised by using aromatic hydrazide and the corresponding 1,3,4-oxadiazole 38–44 from Schiff base have been synthesised. In general the 1H NMR spectra of the compound show one singlet between δ 5 to δ 6 CH₂O. The Schiff bases explained the presence of –CONH (δ 10–12) and –N=CH from the presence of one singlet from δ 8 to δ 9. The next step of the synthesis of 1,3,4-oxadiazole, the disappearance of –CONH and –N=CH peaks confirm the formation of 1,3,4-oxadiazole (Scheme 2).

Scheme 2

3.2. Anticancer Activity

Eleven compounds have been evaluated for their anticancer activity by NCI, USA. The observed anticancer screening of the compounds is given in Table 1. The two compounds were selected for five-dose assay; these compounds are given in Table 2. Anticancer data reveals that compound 7 shows the growth percent ranges between 25.58 and 112.94, and the most sensitive cell lines are BT-549 (breast cancer) and T-47D (breast cancer) with the cell proliferation of 25.58 and 36.56, respectively. Compound 17 shows the growth percent ranges from 66.38 to 119.29, and the most sensitive cell lines are UO-31 (renal cancer) and SNB-75 (CNS cancer) with the cell proliferation of 66.38 and 80.69, respectively. Compound 18 shows the growth percent ranges from 7.52 to 120.39, and the most sensitive cell lines are HCT-116 (colon cancer), RPMI-8226 (leukemia), and CCRF-CEM (leukemia) with the cell proliferation of 7.52, 15.32, and 18.96, respectively. Compound 20 shows the growth percent ranges from 58.38 to 168.13, and the most sensitive cell lines are UO-31 (renal cancer) and MCF7 (breast cancer) with the cell proliferation of 58.38 and 59.04, respectively. Compound 21 shows the growth percent ranges from 73.22 to 322.59, and the most sensitive cell lines are SNB-75 (CNS cancer) and UO-31 (renal cancer) with the cell proliferation of 73.22 and 75.50, respectively. Compound 22 shows the growth percent ranges from 68.36 to 116.40, and the most sensitive cell lines are UO-31 (renal cancer) and SNB-75 (CNS cancer) with the cell proliferation of 68.36 and 70.69, respectively. Compound 24 shows the growth percent ranges from 71.08 to 132.21, and the most sensitive cell lines are UO-31 (renal cancer) and K-562 (leukemia) with the cell proliferation of 71.08 and 74.44, respectively. Compound 27 shows the growth percent ranges from −18.17 to 94.56, and the most sensitive cell lines are HL-60TB (leukemia), MOLT-4 (leukemia), and SR (leukemia) with the cell proliferation of −18.17, −13.79, and −7.63, respectively. Compound 38 shows the growth percent ranges from 22.17 to 107.52, and the most sensitive cell lines are CCRF-CEM (leukemia) and HCT-116 (colon cancer) with the cell proliferation of 22.17 and 22.22, respectively. Compound 40 shows the growth percent ranges from 52.19 to 136.93, and the most sensitive cell lines are UO-31 (renal cancer) and HOP-92 (non-small cell lung cancer) with the cell proliferation of 52.19 and 65.04, respectively. Compound 42 shows the growth percent ranges from 54.46 to 140.07, and the most sensitive cell lines are UO-31 (renal cancer) and SNB-75 (CNS cancer) with the cell proliferation of 54.46 and 65.12, respectively.

Table 1: Sixty human tumor cell lines anticancer screening data of 1,3,4-oxadiazole analogue.

Panel/cell line
Growth percent in one dose assay

Compound

(NSC code)
7

(776963)
17

(776964)
18

(776965)
20

(776966)
21

(776967)
22

(776968)
24

(776969)
27

(776971)
38

(776970)
40

(776973)
42

(776972)

Leukemia

    CCRF-CEM
62.29
97.80
18.96
96.39
97.48
95.05
96.04
0.73
22.17
88.72
91.95

    HL-60(TB)
62.07
84.99
27.06
93.94
87.64
92.65
84.86
18.17
70.13
100.01
94.79

    K-562
57.10
96.88
30.83
94.02
89.08
73.62
74.44
−3.18
24.16
86.70
92.41

    MOLT-4
38.52
93.82
57.10
81.63
98.55
84.81
82.67
−13.79
58.84
80.98
80.79

    RPMI-8226
46.61
103.90
15.32
90.25
105.14
99.66
91.19
−4.32
62.44
82.45
94.31

    SR
43.32
100.48
31.61
79.12
108.64
92.79
86.39
−7.63
NT
75.27
85.97

Non-small cell lung cancer

    A549/ATC
68.28
102.26
83.29
99.50
101.27
100.60
103.01
81.28
82.82
88.52
100.80

    HOP-62
75.35
94.46
82.64
93.91
99.00
91.48
94.50
49.80
74.55
92.66
87.05

    HOP-92
48.46
101.70
76.22
93.69
99.25
96.45
101.84
14.22
29.71
65.04
73.35

    NCI-H226
71.75
105.00
85.35
92.81
99.06
88.51
95.88
64.92
71.42
81.09
92.83

    NCI-H23
75.93
93.51
74.68
92.88
98.68
87.99
94.37
66.54
72.86
86.03
87.52

    NCI-H322M
93.43
106.90
92.29
85.97
107.44
NT
NT
92.32
78.67
88.95
107.35

    NCI-H460
85.87
107.30
92.22
104.87
109.52
105.19
104.90
94.15
97.77
95.26
102.46

    NCI-H522
63.25
100.15
71.20
83.30
89.60
102.67
95.45
70.22
75.33
90.31
96.41

Colon Cancer

    COLO 205
80.21
105.24
64.37
97.14
104.48
98.73
97.24
84.59
88.67
92.43
102.20

    HCC-2998
85.93
99.22
78.89
105.11
101.20
98.41
99.35
64.49
91.02
99.13
102.31

    HCT-116
52.32
98.66
7.52
86.71
107.15
88.92
93.41
−2.01
22.22
76.72
93.59

    HCT-15
62.63
99.53
48.99
99.71
106.48
100.05
94.38
17.48
59.61
82.78
93.26

    HT29
69.34
110.21
57.87
103.09
106.76
116.20
102.94
4.53
87.36
77.61
104.15

    KM12
75.93
102.58
77.76
99.64
101.47
101.95
102.29
16.75
78.55
87.48
96.72

    SW-620
88.64
110.90
44.97
108.56
111.64
104.62
105.48
18.07
35.64
94.63
105.16

CNS cancer

    SF-268
63.84
100.31
78.44
100.92
105.11
98.48
97.26
20.56
79.10
95.00
101.65

    SF-295
76.15
101.14
99.71
100.44
101.59
104.07
103.01
92.01
99.41
97.56
99.73

    SF-539
92.51
105.21
80.83
98.30
93.04
93.80
104.84
63.34
78.31
89.57
95.69

    SNB-19
81.62
99.60
85.99
104.39
106.66
107.24
118.35
52.42
86.69
100.65
102.12

    SNB-75
58.53
80.69
69.28
70.05
73.22
70.69
79.63
54.90
51.42
68.98
65.12

    U251
82.46
103.79
72.36
98.35
97.23
91.91
98.31
42.97
71.06
88.68
97.88

Melanoma

    LOX IMVI
63.23
93.92
35.03
97.46
94.55
87.02
94.83
19.62
67.22
88.33
85.77

    MALME-3M
77.64
91.22
55.80
95.90
93.74
99.30
92.28
72.49
98.95
123.55
99.75

    M14
82.44
99.10
65.84
104.89
99.12
101.29
103.24
45.50
83.29
97.31
98.93

    MDA-MB-435
70.53
104.12
52.86
100.61
104.79
104.95
102.28
50.75
90.57
100.57
101.98

    SK-MEL-2
92.34
108.70
78.37
101.15
92.57
113.85
112.61
89.78
87.92
91.80
103.20

    SK-MEL-28
112.94
112.37
101.46
115.05
107.29
116.40
116.82
90.94
107.52
110.01
104.89

    SK-MEL-5
62.94
103.93
56.83
102.49
100.93
99.16
100.67
80.51
95.51
99.00
98.47

    UACC-257
83.64
105.12
79.98
113.86
107.46
108.60
111.79
94.56
99.85
105.57
99.76

    UACC-62
59.62
95.76
47.86
85.07
96.49
95.85
107.63
50.78
66.60
72.73
75.35

Ovarian cancer

    IGROV1
76.24
113.11
65.98
83.58
104.80
111.13
132.21
37.80
68.88
73.42
76.86

    OVCAR-3
49.61
106.56
69.55
113.21
111.72
100.92
107.68
35.71
88.39
94.52
105.76

    OVCAR-4
50.34
95.67
61.34
82.18
97.13
86.48
103.76
53.88
72.53
71.06
82.16

    OVCAR-5
106.83
94.49
120.39
114.36
100.24
103.17
120.08
87.66
96.39
96.96
94.41

    OVCAR-8
70.89
101.90
57.81
103.22
107.61
95.51
99.33
25.47
76.36
90.40
96.99

    NCI/ADR-RES
62.13
101.99
89.85
93.91
103.13
90.74
95.32
34.60
68.12
85.72
94.68

    SK-OV-3
90.18
3 97.22
92.78
91.03
97.60
88.65
103.94
77.34
81.98
87.32
89.99

Renal cancer

    786-0
40.52
98.54
58.27
93.10
99.88
93.03
100.61
62.73
70.97
90.18
93.77

    A498
57.65
110.18
105.94
107.33
95.15
78.05
99.26
54.08
60.34
65.84
96.42

    ACHN
78.17
106.04
65.89
94.78
109.02
105.23
103.76
49.86
74.96
88.72
92.40

    RXF 393
75.91
111.91
76.07
101.43
109.85
103.21
105.90
60.28
87.66
91.37
98.87

    SN12C
73.98
95.38
74.05
109.91
105.74
100.61
NT
29.44
86.85
91.91
91.68

    TK-10
85.06
114.13
111.84
168.13
96.89
104.18
94.72
77.13
106.65
136.93
140.07

    UO-31
34.06
66.38
39.98
58.38
75.50
68.36
71.08
8.45
23.47
52.19
54.46

Prostate cancer

    PC-3
58.32
96.94
65.48
82.75
98.08
90.66
86.35
46.23
71.58
76.86
83.03

    DU-145
58.80
119.29
71.06
107.46
108.55
97.39
106.30
63.49
99.19
98.06
116.21

Breast cancer

    MCF7
50.02
93.06
20.47
59.04
91.23
91.22
88.77
11.59
39.72
84.08
85.66

    MDA-MB-231/ATCC
54.03
96.65
79.63
91.54
120.58
104.47
105.94
47.68
61.51
78.25
71.62

    HS 578T
79.72
110.45
90.07
104.25
132.59
89.18
100.48
72.43
86.82
93.19
97.10

    BT-549
73.60
93.87
48.94
92.07
91.04
86.09
95.84
14.67
83.85
93.88
91.31

    T-47D
25.58
86.17
42.22
78.22
95.06
86.86
93.64
48.89
55.68
74.73
82.45

    MDA-MB-468
36.56
110.38
53.93
90.74
102.81
102.12
103.17
92.11
95.67
96.62
109.56

Mean
68.21
100.70
66.23
96.41
100.99
96.26
99.33
46.61
73.77
88.86
94.16

Delta
42.63
34.32
58.71
38.03
27.77
27.90
28.25
64.78
51.60
36.67
39.70

Range
87.36
52.91
112.87
109.75
59.37
48.04
61.13
112.73
85.35
84.74
85.61

Table 2: Five dose vitro testing results of compound.

Panel/cell line
18 (776965)
27 (776971)

GI₅₀
TGI
LC₅₀
GI₅₀
TGI
LC₅₀

Leukemia

    CCRF-CEM
1.70
7.79
>100
0.414
3.74
>100

    HL-60(TB)
3.43
21.2
>100
2.85
7.88
>100

    K-562
3.29
14.4
>100
2.59
>100
>100

    MOLT-4
2.69
9.22
>100
2.18
7.89
>100

    RPMI-8226
1.94
6.67
>100
2.39
8.45
>100

    SR
2.03
10.9
>100
7.34
8.54
>100

Non-small cell lung Cancer

    A549/ATCC
15.7
>100
>100
8.49
24.2
62.3

    HOP-62
12.6
34.3
93.5
2.98
13.0
52.2

    HOP-92
3.34
15.3
53.3
1.27
5.37
29.2

    NCI-H226
11.5
94.4
>100
5.99
31.4
>100

    NCI-H23
11.3
39.5
>100
4.66
20.7
83.1

    NCI-H322M
15.8
34.4
75.1
14.9
34.4
79.6

    NCI-H460
6.63
28.3
>100
10.4
24.4
57.1

    NCI-H522
2.27
5.90
26.7
6.34
21.1
55.6

Colon cancer

    COLO 205
3.55
13.2
44.9
1.89
4.44
12.3

    HCC-2998
12.7
27.5
59.7
4.40
15.3
50.9

    HCT-116
1.41
3.10
6.83
0.431
1.64
5.82

    HCT-15
3.30
13.5
44.9
2.13
7.69
44.0

    HT29
3.78
12.9
83.3
2.02
4.43
9.70

    KM12
10.4
28.4
77.9
2.85
11.8
96.5

    SW-620
1.87
4.16
9.25
1.08
4.79
32.4

CNS cancer

    SF-268
10.7
42.0
>100
3.41
15.9
69.8

    SF-295
11.2
32.2
92.7
3.48
14.1
42.1

    SNB-19
12.9
38.1
>100
3.78
17.0
63.4

    SNB-75
6.07
21.4
53.5
2.16
9.74
45.8

    U251
4.12
14.9
43.3
1.58
3.62
8.29

Melanoma

    LOX IMVI
1.74
4.30
13.1
1.59
4.32
17.1

    MALME-3M
3.94
16.2
89.6
3.65
15.6
>100

    M14
3.16
15.2
54.7
2.33
7.40
34.5

    MDA-MB-435
3.51
17.5
77.8
3.06
11.9
40.5

    SK-MEL-5
3.43
16.4
55.2
1.90
3.97
8.30

    UACC-257
4.79
24.4
88.2
3.28
14.9
59.4

    UACC-62
3.43
15.6
47.7
5.62
20.7
53.4

Ovarian cancer

    IGROV1
5.20
27.1
>100
3.25
22.0
>100

    OVCAR-3
3.25
11.0
35.4
2.41
6.65
35.1

    OVCAR-4
4.23
18.3
47.2
2.36
10.2
>100

    OVCAR-8
2.71
NT
>100
2.12
7.52
>100

    NCI/ADR-RES
14.4
71.1
>100
2.84
10.9
>100

    SK-OV-3
18.3
38.1
79.3
11.8
32.7
90.3

Renal cancer

    786-0
4.01
14.6
58.2
3.09
11.8
51.4

    A498
13.3
27.1
55.1
0.409
18.7
44.9

    CAKI-1
3.65
14.4
48.2
2.29
14.9
>100

    RXF 393
2.93
10.9
79.1
2.71
10.6
45.0

    SN12C
3.46
28.2
>100
2.76
11.9
>100

    TK-10
5.23
16.0
54.1
3.91
9.92
96.5

    UO-31
1.72
3.72
8.05
1.19
10.2
48.4

Prostate cancer

    PC-3
4.16
70.6
>100
2.71
15.4
>100

    DU-145
5.18
18.5
48.9
5.46
45.7
>100

Breast cancer

    MCF7
2.41
12.9
58.5
0.949
5.38
55.6

    MDA-MB-231/ATCC
3.29
14.7
>100
1.64
4.62
70.7

    HS 578T
13.3
>100
>100
4.39
33.8
>100

    BT-549
2.56
10.2
34.2
1.77
4.06
9.31

    T-47D
3.04
17.1
>100
2.61
14.6
>100

    MDA-MB-468
2.29
9.87
59.2
3.95
18.3
74.4

The result of anticancer activity of the five-dose assay of the selected compounds amongst their respected series is given in Table 2. Compound 18 (NSC-776965) shows GI₅₀ values ranges from 1.41 to 15.8 μM, where the cell line of colon cancer recorded the best results with values ranging 10.4 μM (Figure 1). Only two cancer cell lines presented TGI value with >100 μM, and the value of the best result has been recorded on UO-31 (renal cancer) with value 3.72. In the 20 cell lines, Compound 18 shows LC₅₀ value with >100 03BCM. Compound 27 (NSC-776971) shows GI₅₀ values ranging from 0.40 to 14.9 μM, where the cell line of renal cancer recorded the best results with values ranging between 0.40 and 3.91 μM (Figure 2). Only one cancer cell line presented TGI value with >100 μM, and the value of the best results has been recorded on HCT-116 (colon cancer) with the value of 1.64. In the 18 cell lines, Compound 27 shows LC₅₀ value with >100 μM.

Figure 1

Figure 2

4. Conclusion

The novel series of 1,3,4-oxadiazole analogues have been synthesized in good yields and the anticancer activity showed good results in two compounds, that is, 18, 27 (NSC 776965 and NSC 776971). The present studies reveal that compound 27 is a potent lead compound for anticancer drug discovery and further research. The 1,3,4-oxadiazole anlogue provides a valuable new therapeutic intervention for the treatment of cancer disease.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgments

The authors are so much grateful to Dr. O.P. Agarwal, Managing Director, NIET, for providing the research facilities and IIT, Delhi, for providing the spectral data. The authors also wish to express their thanks to all the staff of the National Cancer Institute, Betehesda, MD, USA, for in vitro evaluation of anticancer activity. We would also like to thanks Dr. Vipin Kumar and Mr. Rajnish Kumar for the kind support for preparing the paper.

References

P. Anand, A. B. Kunnumakara, C. Sundaram et al., “Cancer is a preventable disease that requires major lifestyle changes,” Pharmceutical Research, vol. 25, no. 9, pp. 2097–2116, 2008.

http://en.wikipedia.org/wiki/Cancer

http://jnci.oxfordjournals.org/content/early/2013/01/03/jnci.djs491.full

R. Gudipati, R. N. R. Anreddy, and S. Manda, “Synthesis, characterization and anticancer activity of certain 3-{4-(5-mercapto-1,3,4-oxadiazole-2-yl)phenylimino}indolin-2-one derivatives,” Saudi Pharmaceutical Journal, vol. 19, no. 3, pp. 153–158, 2011.

L. Jin, J. Chen, B. Song et al., “Synthesis, structure, and bioactivity of N′-substituted benzylidene-3,4,5-trimethoxybenzohydrazide and 3-acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 19, pp. 5036–5040, 2006.

R. R. Somani and P. Y. Shirodkar, “Oxadiazole: a biologically active heterocycles,” Der Pharma Chemica, vol. 1, no. 1, pp. 130–140, 2009.

M. Dabiri, P. Salehi, M. Baghbanzadeh, and M. Bahramnejad, “A facile procedure for the one-pot synthesis of unsymmetrical 2,5-disubstituted 1,3,4-oxadiazoles,” Tetrahedron Letters, vol. 47, no. 39, pp. 6983–6986, 2006.

R. T. Steigbigel, D. A. Cooper, P. N. Kumar et al., “Raltegravir with optimized background therapy for resistant HIV-1 infection,” The New England Journal of Medicine, vol. 359, no. 4, pp. 339–354, 2008.

M. Ogata, H. Atobe, H. Kushida, and K. Yamamoto, “In vitro sensitivity of mycoplasmas isolated from various animals and sewage to antibiotics and nitrofurans.,” Journal of Antibiotics, vol. 24, no. 7, pp. 443–451, 1971.

S. Vardan, H. Smulyan, S. Mookherjee, and R. Eich, “Effects of tiodazosin, a new antihypertensive, hemodynamics and clinical variables,” Clinical Pharmacology and Therapeutics, vol. 34, no. 3, pp. 290–296, 1983.

R. Schlecker and P. C. Thieme, “The synthesis of antihypertensive 3-(1,3,4-oxadiazol-2-yl) phenoxypropanolamines,” Tetrahedron, vol. 44, no. 11, pp. 3289–3294, 1988.

M. Shaharyar, A. Mazumder, and M. J. Ahsan, “Synthesis, characterization and anticancer evaluation of 2-(naphthalen-1-ylmethyl/naphthalen-2-yloxymethyl)-1-[5-(substituted phenyl)-[1,3,4]oxadiazol-2-ylmethyl]-1H-benzimidazole,” Arabian Journal of Chemistry, 2013.

L. Jin, J. Chen, B. Song et al., “Synthesis, structure, and bioactivity of N ′-substituted benzylidene-3,4,5-trimethoxybenzohydrazide and 3-acetyl-2-substituted phenyl-5-(3,4,5-trimethoxyphenyl)-2,3-dihydro-1,3,4-oxadiazole derivatives,” Bioorganic and Medicinal Chemistry Letters, vol. 16, no. 19, pp. 5036–5040, 2006.

B. S. Holla, K. N. Poojary, K. S. Bhat, M. Ashok, and B. Poojary, “Synthesis and anticancer activity studies on some 2-chloro-1,4-bis-(5- substituted-1,3,4-oxadiazol-2-ylmethyleneoxy) phenylene derivatives,” Indian Journal of Chemistry B: Organic and Medicinal Chemistry, vol. 44, no. 8, pp. 1669–1673, 2005.

P. Sengupta, D. K. Dash, V. C. Yeligar et al., “Evaluation of anticancer activity of some 1,3,4-oxadiazole derivatives,” Indian Journal of Chemistry B, vol. 47, no. 3, pp. 460–462, 2008.

M. J. Ahsan, V. P. S. Rathod, M. Singh et al., “Synthesis, anticancer and molecular docking studies of 2-(4-chlorophenyl)-5-aryl-1,3,4-oxadiazole analogues,” Medicinal Chemistry, vol. 3, no. 4, pp. 294–297, 2013.

A. Almasirad, S. A. Tabatabai, M. Faizi et al., “Synthesis and anticonvulsant activity of new 2-substituted-5-[2-(2- fluorophenoxy)phenyl]-1,3,4-oxadiazoles and 1,2,4-triazoles,” Bioorganic and Medicinal Chemistry Letters, vol. 14, no. 24, pp. 6057–6059, 2004.

M. Abdel-Aziz, G. E. A. Abuo-Rahma, and A. A. Hassan, “Synthesis of novel pyrazole derivatives and evaluation of their antidepressant and anticonvulsant activities,” European Journal of Medicinal Chemistry, vol. 44, no. 9, pp. 3480–3487, 2009.

M. Shaharyar, A. Mazumder, R. Garg, and R. D. Pandey, “Synthesis, characterization and pharmacological screening of novel benzimidazole derivatives,” Arabian Journal of Chemistry, 2011.

N. P. Shetgiri and B. K. Nayak, “Synthesis and antimicrobial activities of oxadiazoles, phthalazines and indolinones,” Indian Journal of Chemistry B, vol. 44, no. 6, pp. 1267–1272, 2005.

K. Manjunatha, B. Poojary, P. L. Lobo, J. Fernandes, and N. S. Kumari, “Synthesis and biological evaluation of some 1,3,4-oxadiazole derivatives,” European Journal of Medicinal Chemistry, vol. 45, no. 11, pp. 5225–5233, 2010.

M. Shailaja, M. Anitha, A. Manjula, and B. V. Rao, “Synthesis and biological activity of novel 2,5-disubstituted-l,3,4- oxadiazoles,” Indian Journal of Chemistry B, vol. 49, no. 8, pp. 1088–1097, 2010.

V. V. Mulwad and A. C. Chaskar, “Synthesis and antibacterial activity of new oxadiazolo[1,3,5]-triazine, 1,2,4 triazolo and thiadiazolo 1,3,4 oxadiazole derivatives,” Indian Journal of Chemistry B: Organic and Medicinal Chemistry, vol. 45, no. 7, pp. 1710–1715, 2006.

K. F. Ansari and C. Lal, “Synthesis and evaluation of some new benzimidazole derivatives as potential antimicrobial agents,” European Journal of Medicinal Chemistry, vol. 44, no. 5, pp. 2294–2299, 2009.

Salahuddin, M. Shaharyar, A. Mazumder, and M. M. Abdullah, “Synthesis, characterization and antimicrobial activity of 1,3,4-oxadiazole bearing 1H-benzimidazole derivatives,” Arabian Journal of Chemistry, 2012.

S. V. Bhandari, K. G. Bothara, M. K. Raut, A. A. Patil, A. P. Sarkate, and V. J. Mokale, “Design, synthesis and evaluation of antiinflammatory, analgesic and ulcerogenicity studies of novel s-substituted phenacyl-1,3,4-oxadiazole-2-thiol and schiff bases of diclofenac acid as nonulcerogenic derivatives,” Bioorganic and Medicinal Chemistry, vol. 16, no. 4, pp. 1822–1831, 2008.

D. Dewangan, A. Pandey, T. Sivakumar, R. Rajavel, and R. D. Dubey, “Synthesis of some Novel 2, 5-Disubstituted 1, 3, 4-Oxadiazole and its analgesic, Anti-Inflammatory, Anti-Bacterial and Anti-Tubercular Activity,” International Journal of ChemTech Research, vol. 3, no. 3, pp. 1397–1412, 2010.

M. Amir, S. A. Javed, and H. Kumar, “Synthesis of some 1,3,4-oxadiazole derivatives as potential anti-inflammatory agents,” Indian Journal of Chemistry B, vol. 46, no. 6, pp. 1014–1019, 2007.

B. Jayashankar, K. M. Lokanath Rai, N. Baskaran, and H. S. Sathish, “Synthesis and pharmacological evaluation of 1,3,4-oxadiazole bearing bis(heterocycle) derivatives as anti-inflammatory and analgesic agents,” European Journal of Medicinal Chemistry, vol. 44, no. 10, pp. 3898–3902, 2009.

H. Lv, B. Zhao, J. Li et al., “The synthesis, characterization and optical properties of novel, substituted, pyrazoly 1,3,4-oxadiazole derivatives,” Dyes and Pigments, vol. 86, no. 1, pp. 25–31, 2010.

S. J. Gilani, S. A. Khan, and N. Siddiqui, “Synthesis and pharmacological evaluation of condensed heterocyclic 6-substituted 1,2,4-triazolo-[3,4-b]-1,3,4-thiadiazole and 1,3,4-oxadiazole derivatives of isoniazid,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 16, pp. 4762–4765, 2010.

M. A. Ali and M. Shaharyar, “Oxadiazole mannich bases: Synthesis and antimycobacterial activity,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 12, pp. 3314–3316, 2007.

M. J. Ahsan, H. Khalilullah, S. Yasmin, S. S. Jadav, and J. Govindasamy, “Synthesis, characterisation, and in vitro anti-cancer activity of curcumin analogues bearing pyrazole/pyrimidine ring targeting EGFR tyrosine kinase,” BioMed Research International, vol. 2013, Article ID 239354, 14 pages, 2013.

K. K. Jha, A. Samad, Y. Kumar et al., “Design, synthesis and biological evaluation of 1,3,4-oxadiazole derivatives,” European Journal of Medicinal Chemistry, vol. 45, no. 11, pp. 4963–4967, 2010.

http://dtp.nci.nih.gov

A. Monks, D. Scudiero, P. Skehan et al., “Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines,” Journal of the National Cancer Institute, vol. 83, no. 11, pp. 757–766, 1991.

M. R. Body and K. D. Paull, “Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen,” Drug Development Research, vol. 34, no. 2, pp. 91–109, 1995.

R. H. Shoemaker, “The NCI60 human tumour cell line anticancer drug screen,” Nature Reviews Cancer, vol. 6, no. 10, pp. 813–823, 2006.

S. A. Shahzad, M. Yar, M. Bajda et al., “Synthesis and biological Evaluation of novel oxadiazole derivatives: a new class of thymidine phosphorylase inhibitor as potential anti-tumor agents,” Bioorganic and Medicinal Chemistry, vol. 22, no. 3, pp. 1008–1015, 2014.

M. J Ahsan, J. Sharma, S. Bhatia, P. K. Goyal, K. Shankhala, and M. Didel, “Synthesis of 2,5-disubstituted-1,3,4-oxadiazole analogs as novel anticancer and antimicrobial agents,” Letters in Drug design and Discovery, vol. 11, no. 4, pp. 413–419, 2014.